Recently, Mouron et al. conducted a phosphoproteomic screening of 130 HER2-negative female BC cases in treatment with Paclitaxel and found that patients with higher levels of CDK4 and filamin-A phosphorylation had a 90% likelihood of obtaining a pathologic complete response (pCR) to Paclitaxel [122]. This evidence concerns the gene ERBB2 and breast cancer.